Targeting miR-148b-5p Inhibits Immunity Microenvironment and Gastric Cancer Progression

Background MicroRNAs (miRNAs) have been discovered to dictate the development of various tumors. However, studies on the roles of miRNAs in the progression of gastric cancer (GC) are still lacking. Methods Herein, by analyzing GC cell lines and patients samples, we observed that miR-148b-5p was significantly downregulated in GC. We also confirmed that miR-148b-5p overexpression significantly inhibited GC cell proliferation and invasion in vitro and in vivo. Results Overexpression of miR-148b-5p not only reprogrammed the metabolic properties of GC but also regulated the immune microenvironment by shifting lymphocyte and myeloid populations. Mechanistically, ATPIF1, an important glycolysis-associated gene, was identified as a direct target of miR-148b-5p and mediated the effect of miR-148b-5p. Notably, the low level of miR-148b-5p was significantly related with poor prognosis of GC patients (P < 0.001). Importantly, the levels of miR-148b-5p significantly changed the sensitivity of GC cells to several anti-cancer drugs (Doxorubicin, P < 0.05, Paclitaxel, P < 0.01, Docetaxel, P < 0.05). Conclusions Targeting miR-148b-5p inhibits immunity microenvironment and gastric cancer progression.

[1]  H. Grabsch,et al.  Gastric cancer , 2020, The Lancet.

[2]  Zhiyong Zhang,et al.  Targeting CLK3 inhibits the progression of cholangiocarcinoma by reprogramming nucleotide metabolism , 2020, The Journal of experimental medicine.

[3]  Zhiyong Zhang,et al.  Hypoxia-induced acetylation of PAK1 enhances autophagy and promotes brain tumorigenesis via phosphorylating ATG5 , 2020, Autophagy.

[4]  C. Garrido,et al.  Exosomal miRNA: Small Molecules, Big Impact in Colorectal Cancer , 2019, Journal of oncology.

[5]  Guideng Li,et al.  MicroRNA-125 in immunity and cancer. , 2019, Cancer letters.

[6]  Jason S. Lewis,et al.  Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors , 2019, The Journal of Nuclear Medicine.

[7]  Zhiyong Zhang,et al.  MiR-374b re-sensitizes hepatocellular carcinoma cells to sorafenib therapy by antagonizing PKM2-mediated glycolysis pathway. , 2019, American journal of cancer research.

[8]  Kyoung Hyoun Kim,et al.  Tumor Suppressor miRNA-204-5p Regulates Growth, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer. , 2019, Cancer research.

[9]  L. Lartigue,et al.  Control of the Antitumor Immune Response by Cancer Metabolism , 2019, Cells.

[10]  Hongwei,et al.  Dyrk 3 loss activates the purine metabolism and promotes hepatocellular carcinoma progression , 2019 .

[11]  Husheng Wang,et al.  Exosomes Released from Tumor-Associated Macrophages Transfer miRNAs That Induce a Treg/Th17 Cell Imbalance in Epithelial Ovarian Cancer , 2018, Cancer Immunology Research.

[12]  Zhiyong Zhang,et al.  Long noncoding RNA SNHG6 promotes the progression of colorectal cancer through sponging miR-760 and activation of FOXC1 , 2018, OncoTargets and therapy.

[13]  Y. Liu,et al.  miR-483 is down-regulated in gastric cancer and suppresses cell proliferation, invasion and protein O-GlcNAcylation by targeting OGT. , 2018, Neoplasma.

[14]  Nayoung K. D. Kim,et al.  Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability , 2018, ESMO Open.

[15]  M. Salto‐Tellez,et al.  HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee , 2018, Journal of Clinical Pathology.

[16]  Zhiyong Zhang,et al.  Long noncoding RNA SNHG6 promotes the progression of colorectal cancer through sponging miR-760 and activation of FOXC1 , 2018, OncoTargets and therapy.

[17]  Zhiyong Zhang,et al.  Targeting posttranslational modifications of RIOK1 inhibits the progression of colorectal and gastric cancers , 2017, bioRxiv.

[18]  T. Kalbfleisch,et al.  The miR-29 transcriptome in endocrine-sensitive and resistant breast cancer cells , 2017, Scientific Reports.

[19]  S. Wessler,et al.  Oxidative Phosphorylation System in Gastric Carcinomas and Gastritis , 2017, Oxidative medicine and cellular longevity.

[20]  Zhiyong Zhang,et al.  HnRNPK/miR-223/FBXW7 feedback cascade promotes pancreatic cancer cell growth and invasion , 2017, Oncotarget.

[21]  Wei Huang,et al.  MiRNA-543 promotes osteosarcoma cell proliferation and glycolysis by partially suppressing PRMT9 and stabilizing HIF-1α protein , 2016, Oncotarget.

[22]  I. Riquelme,et al.  Tools for Sequence-Based miRNA Target Prediction: What to Choose? , 2016, International journal of molecular sciences.

[23]  R. Lupi,et al.  Neuroprotective coordination of cell mitophagy by the ATPase Inhibitory Factor 1. , 2016, Pharmacological research.

[24]  D. Matei,et al.  Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study , 2015, PloS one.

[25]  E. Lengyel,et al.  MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment , 2015, Oncogene.

[26]  Ying-jian Liang,et al.  Reciprocal activation between ATPase inhibitory factor 1 and NF‐κB drives hepatocellular carcinoma angiogenesis and metastasis , 2014, Hepatology.

[27]  N. Lu,et al.  HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population , 2013, Diagnostic Pathology.